Sunday, November 8, 2026

USD/EUR Drops By 2% In The Last 21 Sessions

USD/EUR Drops By 2% In The Last 21 Sessions

(VIANEWS) - USD/EUR (USDEUR) has been up by 2.08% for the last 21 sessions. At 00:12 EST on Friday, 21 July, USD/EUR (USDEUR) is $0.90.

USD/EUR's yearly highs and lows, it's 1.218% up from its 52-week low and 14.358% down from its 52-week high.

Volatility

USD/EUR's last week, last month's, and last quarter's current intraday variation average was a positive 0.14%, a negative 0.09%, and a positive 0.33%, respectively.

USD/EUR's highest amplitude of average volatility was 0.20% (last week), 0.35% (last month), and 0.33% (last quarter), respectively.

Forex Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, USD/EUR's Forex is considered to be oversold (<=20).

News about

  • Eur/usd: room to correct lower before the end of the week – ING. According to FXStreet on Wednesday, 19 July, "For now, they've preferred to keep expectations close to two rate hikes (43 bps) as EUR/USD has held above 1.1200 thanks to the Dollar's still softish momentum.", "We still see room for the overvalued EUR/USD (in the short-term) to correct lower before the end of the week, with a move back to the 1.1150/1.1170 region as a first step."
  • Eur/usd price analysis: bulls flirt with 100-hour SMA support breakpoint, around 1.1225 area. According to FXStreet on Thursday, 20 July, "From a technical perspective, the overnight breakdown through a three-week-old trading range and the 100-hour Simple Moving Average (SMA) warrants some caution before placing fresh bullish bets around the EUR/USD pair. ", "This, in turn, is seen as a key factor acting as a tailwind for the EUR/USD pair, though less hawkish remarks by several European Central Bank (ECB) policymakers this week could cap any meaningful gains, at least for the time being."
  • Eur/usd forex signal: on the cusp of a short-term pullback - 19 July 2023. According to DailyForex on Wednesday, 19 July, "The EUR/USD price was trading at 1.1225, a few pips below this week's high of 1.1275.", "The EUR/USD price will also react to the latest European consumer inflation data. "
  • According to FXStreet on Wednesday, 19 July, "Price action in EUR/USD pair hints at the idea that further gains might be in store in the short-term horizon.", "Furthermore, the constructive view of EUR/USD appears unchanged as long as the pair trades above the key 200-day SMA."
  • Eur/usd extends pullback from 1.1280 resistance as ECB vs. fed divergence appears dicey. According to FXStreet on Wednesday, 19 July, "It's worth observing that mixed headlines surrounding China and optimism at the equity markets also tease the EUR/USD bears amid a sluggish session. ", "With this, the EUR/USD is likely to extend the latest pullback amid a light calendar."

More news about USD/EUR (USDEUR).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com